Notable Upgrades: MiMedx (MDXG), Marvell Technology (MRVL), Knowles Corp (KN), MEI Pharma (MEIP)

MiMedx Group (MDXG) climbed over 4.50% Friday, boosted by Needham analysts who upgraded the name with a ‘Strong Buy’ from ‘Buy’ rating and price target of $13 per share. In a research note published this morning, the broker said the new rating and estimate is based on renewed confidence that the company can exceed consensus 2015 estimates.

On valuation measures, MiMedx Group, Inc. shares are currently priced at 1,092x this year’s forecasted earnings compared to the industry’s (0.78)x earnings multiple. Ticker has a PEG and forward P/E ratio of 11.23 and 51.76, respectively. Price/Sales for the same period is 10.38 while EPS is $0.01. Currently there are 4 analysts that rate MDXG a ‘Buy’, 0 rate it a ‘Hold’. 1 analyst rates it a ‘Sell’. MDXG has a median Wall Street price target of $12.00 with a high target of $14.00.

In the past 52 weeks, shares of Marietta, Georgia-based independent equity REIT have traded between a low of $4.88 and a high of $11.97 and are now at $9.83. Shares are up 30.28% year-over-year ; down 18.65% year-to-date.

Analysts at FBR Capital upgraded their Marvell Technology Group Ltd. (MRVL) rating to ‘Outperform’ from ‘Market Perform’ and set a price target of $21 per share in a research report issued to clients on Friday. The firm believes the stock’s current price level represents a compelling valuation, setup, and risk/reward ratio.

Marvell’s shares closed at $16.40 yesterday. The firm’s PT suggests a potential upside of about 30% from the names’s current PPS of $16.18.

MRVL prints a one year return of 5.67%, and a year-to-date return of 13.10%.

Analysts at Robert W. Baird upgraded shares of Knowles Corporation (KN) to ‘Outperform’ from ‘Neutral’ and lifted their price target to $23 from $20 in a research report issued to clients on Friday. The firm’s new PT points to a potential upside of 18.20% from the stock’s current price-per-share.

Knowles Corporation, currently valued at $1.66B, has a median Wall Street price target of $24.00 with a high target of $28.00. Approximately 4.88M shares have already changed hands, compared to the stock’s average daily volume of 1.63M.

In the past 52 weeks, shares of Itasca, Illinois-based tech company have traded between a low of $17.09 and a high of $33.82 with the 50-day MA and 200-day MA located at $21.79 and $24.02 levels, respectively. Additionally, shares of KN trade at a P/E ratio of 2.35 and have a Relative Strength Index (RSI) and MACD indicator of 42.83 and -2.57, respectively.

KN currently prints a one year loss of about 36%, and a year-to-date loss of 22.55%.

Shares of oncology company MEI Pharma, Inc. (MEIP) are up more than 8% after Bank of America (BAC) analysts today initiated coverage of the name, giving MEI Pharma a ‘Buy’ rating, and price target of $9.00.

MEIP shares recently gained $0.40 to $5.44. The stock is down more than 38% year-over-year and has gained roughly 18% year-to-date. In the past 52 weeks, shares of San Diego, California-based company have traded between a low of $3.57 and a high of $13.98.

MEI Pharma, Inc. closed Thursday at $5.04. The name has a total market cap of $180.94 million.

Be the first to comment

Leave a Reply

Your email address will not be published.


*